Feedback
HRAS Mutation Detection by Pyrosequencing
2012175
Ordering Recommendation

Detects HRAS mutations (codons 12, 13, 61) associated with thyroid cancer.

Mnemonic
HRAS
Methodology
Polymerase Chain Reaction/Pyrosequencing
Performed
Tue, Thu
Reported
5-7 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Tumor tissue. 
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5 micron slides. (Min: 3 slides).
A Fine Needle Aspirate (FNA) smear may also be submitted. Prepare FNA smear with Diff-Quik or equivalent stain by standard methods (air-dried slides are preferred). Number of slides needed is dependent on the tumor cellularity of the smear. (Min: 1 slide). Slide(s) will be destroyed during testing process and will not be returned to client.
Transport block and/or slide(s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. A Fine Needle Aspirate (FNA) specimen stored in saline, PreservCyt or CytoLyt may also be submitted. 
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. 
Unacceptable Conditions
Less than 25 percent tumor. Decalcified specimens. FNA smears with less than 50 tumor cells. 
Remarks
Include surgical pathology report. Tissue block will be returned after testing. 
Stability
FFPE and FNA smears: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
FNA cells unfixed: Ambient: 2 days; Refrigerated: 2 days; Frozen: Unacceptable
FNA cells fixed: Ambient: 3 days; Refrigerated: 14 days; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
This assay detects mutations in codons 12, 13, and 61.
CPT Code(s)
88381; 81403
Components
Component Test Code*Component Chart NameLOINC
2002148Block ID57723-9
2012176HRAS Mutation Detection, Pyrosequencing21719-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases